중재적 종양학 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 기법별, 수기별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Interventional Oncology Market Trends:

The global interventional oncology market size was valued at USD 2.68 billion in 2024 and is projected to grow at a CAGR of 8.55% from 2025 to 2030. This growth can be attributed to the increasing prevalence of cancer, increasing technological advancements in minimally invasive procedures, growing geriatric population, rising focus on early cancer detection, and increasing public and private investments in the field of interventional oncology. There is a significant rise in the number of cancer cases globally, increasing the need for advanced solutions facilitating better cancer care. According to the WHO, in 2022, approximately 20 million new cancer cases and 9.7 million deaths occurred. By 2050, cases are projected to rise to over 35 million, marking a 77% increase in the global cancer burden.

Interventional oncology, with its array of minimally invasive techniques such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and cryoablation, offers significant advantages over traditional surgery, including reduced recovery times and lower complication rates. As the global cancer burden continues to rise, the adoption of these advanced interventional techniques is expected to accelerate, driven by their ability to improve patient outcomes and quality of life.

The rising global incidence of cancer is largely attributed to increasing tobacco use, unhealthy diets, alcohol consumption, air pollution, and physical inactivity. This surge in cancer cases poses a significant challenge for healthcare systems, spurring the development of advanced solutions that offer better results and outcomes. Interventional oncology, which provides a minimally invasive alternative to traditional cancer treatments such as surgery, radiation, and chemotherapy, has become increasingly popular. Its advantages in terms of reduced patient trauma and quicker recovery times are key factors driving market growth.

These staggering statistics highlight the urgent need for effective cancer treatments. Interventional oncology, with its array of minimally invasive techniques such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and cryoablation, offers significant advantages over traditional surgery, including reduced recovery times and lower complication rates. As the global cancer burden continues to rise, the adoption of these advanced interventional techniques is expected to accelerate, driven by their ability to improve patient outcomes and quality of life.

Companies in the industry are actively pursuing various strategies to develop advanced solutions aimed at improving patient treatment and care. For example, in April 2021, Terumo launched its global therapeutic interventional oncology team to achieve excellence in interventional oncology solutions, with the goal of enhancing patient quality of life and survival rates. Such initiatives are expected to spur the development of innovative solutions, increasing the adoption of interventional oncology and driving market growth.

Moreover, increased efforts to develop advanced solutions have led to significant investments from both government and private organizations. In June 2023, Royal Philips announced that the Philips-coordinated IMAGIO consortium of clinical partners received a grant of approximately $25.97 million. This funding is intended to support research on minimally invasive cancer treatments, with a focus on liver cancer, lung cancer, and soft tissue sarcomas. Such investments are crucial for advancing interventional oncology technologies and improving patient outcomes.

Global Interventional Oncology Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global interventional oncology market report based on techniques, procedures, applications, end-use, and region.

• Techniques Outlook (Revenue, USD Million, 2018 - 2030)
• Ablation Therapies
  • Radiofrequency Ablation (RFA)
  • Microwave Ablation (MWA)
  • Cryoablation
  • Laser Ablation
  • Irreversible Electroporation (IRE)
• Embolization Therapies
  • Transarterial Chemoembolization (TACE)
  • Transarterial Radioembolization (TARE)
• Biopsy Techniques
  • Core Needle Biopsy
  • Fine Needle Aspiration (FNA)
• Targeted Therapy Delivery Systems
  • Drug-Eluting Beads
  • Radioembolization
  • Drug-Eluting Stents
  • Injectable Hydrogels and Nanoparticles
  • Other Targeted Therapy Systems
• Image-Guided Procedures
  • Ultrasound Guidance
  • CT Scan Guidance
  • MRI Guidance
  • Fluoroscopy Guidance
• Procedure Outlook (Revenue, USD Million, 2018 - 2030)
• Tumor Ablation
• Tumor Biopsy
• Vascular Interventions
• Palliative Care
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Liver Cancer
• Lung Cancer
• Kidney Cancer
• Prostate Cancer
• Breast Cancer
• Other Cancer
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Specialty Clinics
• Others
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Technique Segment
  • 1.2.2. Procedure Segment
  • 1.2.3. Application Segment
  • 1.2.4. End-use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Interventional Oncology Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of cancer
    • 3.2.1.2. Increasing technological advancements in minimally invasive procedures
    • 3.2.1.3. Growing geriatric population
    • 3.2.1.4. Increasing focus on early cancer detection
    • 3.2.1.5. Increasing public and private investments in the field of interventional oncology
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost associated with interventional oncology
    • 3.2.2.2. Requirement of highly skilled professionals
• 3.3. Interventional Oncology Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Interventional Oncology Market: Technique Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Interventional Oncology Market Product & Service Movement Analysis
• 4.3. Global Interventional Oncology Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
• 4.4. Ablation Therapies
  • 4.4.1. Ablation Therapies market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Radiofrequency Ablation (RFA)
    • 4.4.2.1. Radiofrequency Ablation (RFA) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Microwave Ablation (MWA)
    • 4.4.3.1. Microwave Ablation (MWA) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Cryoablation
    • 4.4.4.1. Cryoablation market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Laser Ablation
    • 4.4.5.1. Laser Ablation market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.6. Irreversible Electroporation (IRE)
    • 4.4.6.1. Irreversible Electroporation (IRE) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Embolization Therapies
  • 4.5.1. Embolization Therapies market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Transarterial Chemoembolization (TACE)
    • 4.5.2.1. Transarterial Chemoembolzation (TACE) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Transarterial Radioembolization (TARE)
    • 4.5.3.1. Transarterial Radioembolization (TARE) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Biopsy Techniques
  • 4.6.1. Biopsy Techniques market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.2. Core Needle Biopsy
    • 4.6.2.1. Core Needle Biopsy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.3. Fine Needle Aspiration (FNA)
    • 4.6.3.1. Fine Needle Aspiration (FNA) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Targeted Therapy Delivery Systems
  • 4.7.1. Drug Delivery Systems market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.2. Drug-Eluting Beads
    • 4.7.2.1. Drug-Eluting Beads market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.3. Radioembolization
    • 4.7.3.1. Radioembolization market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.4. Drug-Eluting Stents
    • 4.7.4.1. Drug-Eluting Stents market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.5. Injectable Hydrogels and Nanoparticles
    • 4.7.5.1. Injectable Hydrogels and Nanoparticles market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.6. Other Targeted Therapy Systems
    • 4.7.6.1. Other Targeted Therapy Systems market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Image-Guided Procedures
  • 4.8.1. Image-Guided Procedures market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.2. Ultrasound Guidance
    • 4.8.2.1. Ultrasound Guidance market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.3. CT Scan Guidance
    • 4.8.3.1. CT Scan Guidance market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.4. MRI Guidance
    • 4.8.4.1. MRI Guidance market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.5. Fluoroscopy Guidance
    • 4.8.5.1. Fluoroscopy Guidance market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Interventional Oncology Market: Procedures Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Interventional Oncology Market Procedures Movement Analysis
• 5.3. Global Interventional Oncology Market Size & Trend Analysis, by Procedures, 2018 to 2030 (USD Million)
• 5.4. Tumor Ablation
  • 5.4.1. Tumor Ablation market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Tumor Biopsy
  • 5.5.1. Tumor Biopsy market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Vascular Interventions
  • 5.6.1. Vascular Interventions market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Palliative Care
  • 5.7.1. Palliative Care market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Interventional Oncology Materials Market: Applications Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Interventional Oncology Market Applications Movement Analysis
• 6.3. Global Interventional Oncology Market Size & Trend Analysis, by Applications, 2018 to 2030 (USD Million)
• 6.4. Liver Cancer
  • 6.4.1. Liver Cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Lung Cancer
  • 6.5.1. Lung Cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Kidney Cancer
  • 6.6.1. Kidney Cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Prostate Cancer
  • 6.7.1. Prostate Cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Breast Cancer
  • 6.8.1. Breast Cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Other Cancer
  • 6.9.1. Other Cancer market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Interventional Oncology Market: End-use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Interventional Oncology Market End Use Movement Analysis
• 7.3. Global Interventional Oncology Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Hospitals
  • 7.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Specialty Clinics
  • 7.5.1. Specialty Clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Interventional Oncology Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. U.S.
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Competitive scenario
    • 8.4.1.3. Regulatory framework
    • 8.4.1.4. Reimbursement scenario
    • 8.4.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Canada
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Competitive scenario
    • 8.4.2.3. Regulatory framework
    • 8.4.2.4. Reimbursement scenario
    • 8.4.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. Mexico
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Competitive scenario
    • 8.4.3.3. Regulatory framework
    • 8.4.3.4. Reimbursement scenario
    • 8.4.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. UK
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Competitive scenario
    • 8.5.1.3. Regulatory framework
    • 8.5.1.4. Reimbursement scenario
    • 8.5.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. Germany
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Competitive scenario
    • 8.5.2.3. Regulatory framework
    • 8.5.2.4. Reimbursement scenario
    • 8.5.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. France
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Competitive scenario
    • 8.5.3.3. Regulatory framework
    • 8.5.3.4. Reimbursement scenario
    • 8.5.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Italy
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Competitive scenario
    • 8.5.4.3. Regulatory framework
    • 8.5.4.4. Reimbursement scenario
    • 8.5.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. Spain
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Competitive scenario
    • 8.5.5.3. Regulatory framework
    • 8.5.5.4. Reimbursement scenario
    • 8.5.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Norway
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Competitive scenario
    • 8.5.6.3. Regulatory framework
    • 8.5.6.4. Reimbursement scenario
    • 8.5.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.7. Sweden
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Competitive scenario
    • 8.5.7.3. Regulatory framework
    • 8.5.7.4. Reimbursement scenario
    • 8.5.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.8. Denmark
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Competitive scenario
    • 8.5.8.3. Regulatory framework
    • 8.5.8.4. Reimbursement scenario
    • 8.5.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Japan
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Competitive scenario
    • 8.6.1.3. Regulatory framework
    • 8.6.1.4. Reimbursement scenario
    • 8.6.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Competitive scenario
    • 8.6.2.3. Regulatory framework
    • 8.6.2.4. Reimbursement scenario
    • 8.6.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. India
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Competitive scenario
    • 8.6.3.3. Regulatory framework
    • 8.6.3.4. Reimbursement scenario
    • 8.6.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Australia
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Competitive scenario
    • 8.6.4.3. Regulatory framework
    • 8.6.4.4. Reimbursement scenario
    • 8.6.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Competitive scenario
    • 8.6.5.3. Regulatory framework
    • 8.6.5.4. Reimbursement scenario
    • 8.6.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Thailand
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Competitive scenario
    • 8.6.6.3. Reimbursement scenario
    • 8.6.6.4. Regulatory framework
    • 8.6.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Brazil
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Competitive scenario
    • 8.7.1.3. Regulatory framework
    • 8.7.1.4. Reimbursement scenario
    • 8.7.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Argentina
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Competitive scenario
    • 8.7.2.3. Regulatory framework
    • 8.7.2.4. Reimbursement scenario
    • 8.7.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. South Africa
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Competitive scenario
    • 8.8.1.3. Regulatory framework
    • 8.8.1.4. Reimbursement scenario
    • 8.8.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. Saudi Arabia
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Competitive scenario
    • 8.8.2.3. Regulatory framework
    • 8.8.2.4. Reimbursement scenario
    • 8.8.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. UAE
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Competitive scenario
    • 8.8.3.3. Regulatory framework
    • 8.8.3.4. Reimbursement scenario
    • 8.8.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.4. Kuwait
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Competitive scenario
    • 8.8.4.3. Regulatory framework
    • 8.8.4.4. Reimbursement scenario
    • 8.8.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2023
• 9.4. Company Profiles/Listing
  • 9.4.1. Medtronic plc
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Boston Scientific Corporation
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Johnson & Johnson (Ethicon)
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Baxter International Inc.
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Cook Medical
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. C.R. Bard Inc. (Acquired by BD)
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. AngioDynamics Inc.
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Stryker Corporation
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. B. Braun Melsungen AG
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Terumo Corporation
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. Siemens Healthineers
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives
  • 9.4.12. GE Healthcare
    • 9.4.12.1. Company overview
    • 9.4.12.2. Financial performance
    • 9.4.12.3. Product benchmarking
    • 9.4.12.4. Strategic initiatives